학술논문

First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
Document Type
Article
Source
In: Journal of Nuclear Medicine. (Journal of Nuclear Medicine, 2024, 65(3):386-393)
Subject
Language
English
ISSN
2159662X
01615505